An observational study in Acute Pancreatitis, Pancreatic Pseudocyst and Pancreatic Necrosis, sponsored by Orlando Health, Inc.. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-09.
Sponsored by Orlando Health, Inc. · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies in Pancreatitis, Acute Necrotizing with a site in United States — 3 open to participants now, 4 under way, none of them phase 3. Pancreatitis, Acute Necrotizing · United States.
Among the 20 studies in Pancreatitis, Acute Necrotizing with a site in United States, this one is one of 2 that started in 2021, is one of 7 observational ones, and was the 17th registered.
75 studies on the registry are indexed under Pancreatitis, Acute Necrotizing; 20 are open to participants now.
Browse Pancreatitis, Acute Necrotizing studies →3 of the 20 studies in Pancreatitis, Acute Necrotizing with a site in United States are open now. Recruiting first, the newest first:
Christopher C. Thompson, MD, MSc · Sites in United States
Ages 18+
Orlando Health, Inc. · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 12 Pancreatitis, Acute Necrotizing studies recruiting now, 9 (75%) set no upper age limit and 3 (25%) stop at 75 or younger; none take children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 2 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 110 is close to the median of 101 across 26 observational studies indexed under Pancreatitis, Acute Necrotizing.
Median enrollment 40 across the 13 interventional studies, 31 across the 7 observational. Of the 16 that completed or were terminated, 4 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 20 have an industry lead sponsor. The 10 most frequent:
Orlando Health, Inc. is the lead sponsor of 28 studies on the registry; 10 are open to participants now.
Orlando Health, Inc. has 3 studies filed under Pancreatitis, Acute Necrotizing — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 20 studies in Pancreatitis, Acute Necrotizing with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Acute pancreatitis is one of the most common gastrointestinal disorders requiring hospitalization worldwide. Pancreatic fluid collections can occur as a consequence of acute and chronic pancreatitis and can result in significant morbidity and mortality, including significant abdominal pain, gastric outlet obstruction, biliary obstruction, organ failure, persistent unwellness, infection and sepsis.
Symptomatic pancreatic fluid collections require treatment, and endoscopic drainage is considered standard of care. The aim of this study is to evaluate the treatment outcomes in patients undergoing standard of care, endoscopic treatment of pancreatic fluid collections.
Acute pancreatitis has an annual incidence of 13-45 cases per 100,000 persons and is one of the most common gastrointestinal disorders requiring hospitalization worldwide. It leads to over a quarter of a million hospital admissions annually in the United States, and inpatient costs exceeding 2.5 billion US dollars. Pancreatic fluid collections can occur as a consequence of acute and chronic pancreatitis and can result in significant morbidity and mortality, including significant abdominal pain, gastric outlet obstruction, biliary obstruction, organ failure, persistent unwellness, infection and sepsis.
Symptomatic pancreatic fluid collections require treatment, and endoscopic drainage is considered standard of care. Endoscopic treatment involves the drainage of the fluid collection into the stomach or duodenum by placement of metal or plastic stents. If clinically indicated, endoscopic necrosectomy is also performed, which is the removal of devitalized pancreatic tissue using the endoscope. Currently the treatment success rate of endoscopic treatment of pancreatic fluid collections exceeds 90%.
The aim of this study is to evaluate the treatment outcomes in patients undergoing standard of care, endoscopic treatment of pancreatic fluid collections.
75 studies on the registry are indexed under Pancreatitis, Acute Necrotizing; 20 are open to participants now.
This study's planned enrollment of 110 is close to the median of 101 across 26 observational studies indexed under Pancreatitis, Acute Necrotizing.
Browse Pancreatitis, Acute Necrotizing studies →Orlando Health, Inc. is the lead sponsor of 28 studies on the registry; 10 are open to participants now.
Compared within Pancreatitis, Acute Necrotizing, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Pancreatitis. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Patients with pancreatic fluid collections
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients with pancreatic fluid collections will be undergoing EUS-guided drainage and/or endoscopic necrosectomy
Treatment outcomes in patients undergoing endoscopic treatment of pancreatic fluid collections according to timing of treatment.
Treatment outcomes in patients undergoing endoscopic treatment of pancreatic fluid collections is assessed as a composite measure consisting of 1) adverse events or 2) need for hospital admission due to underlying disease or procedure-related adverse events, in patients undergoing endoscopic treatment of pancreatic fluid collections, according to timing of treatment.
Time frame: 6 months
Treatment success
Rate of treatment success, defined as the resolution of pancreatic fluid collection on CT scan in association with clinical resolution of symptoms at 6-months from index intervention.
Time frame: 6 months
Number and type of interventions performed
Number of interventions performed to achieve treatment success
Time frame: 6 months
Need for surgical intervention
Need for any surgical intervention in patients undergoing endoscopic therapy for pancreatic fluid collections.
Time frame: 6 months
Technical success of endoscopic interventions in pancreatic fluid collections.
Technical success of endoscopic interventions in pancreatic fluid collections.
Time frame: 6 months
Inflammatory response and organ failure in patients undergoing endoscopic therapy for pancreatic fluid collections.
Rate of inflammatory response and organ failure in patients undergoing endoscopic therapy for pancreatic fluid collections.
Time frame: 6 months
Disease-related adverse events
Rate of disease-related adverse events
Time frame: 6 monthts
Procedure-related adverse events
Procedure-related adverse events in patients undergoing endoscopic management of pancreatic fluid collection
Time frame: 6 months
Timing of intervention
Intervention at 4 weeks since onset of pancreatitis (traditional approach) versus intervention when the area of necrosis is contained or only partially encapsulated.
Time frame: 6 months
Hounsfield units of the pancreatic fluid collection
Impact of hounsfield units in the necrotic collection on endoscopic intervention
Time frame: 6 months
Impact of partial versus full encapsulation of pancreatic fluid collections
Impact of partial versus full encapsulation of pancreatic fluid collections on endoscopic intervention
Time frame: 6 months
Incidence of disconnected pancreatic duct syndrome and sequelae of disconnected pancreatic duct syndrome
Incidence of disconnected pancreatic duct syndrome and sequelae of disconnected pancreatic duct syndrome
Time frame: 6 months
Hospital admission
Rate of hospital readmissions due to disease-related or procedure-related events in patients undergoing endoscopic therapy for pancreatic fluid collections.
Time frame: 6 months
Disease recurrence
Rate of disease recurrence in patients undergoing endoscopic management of pancreatic fluid collections
Time frame: 6 months
Diabetes
Rate of diabetes
Time frame: 6 months
Exocrine pancreatic insufficiency
Rate of exocrine pancreatic insufficiency
Time frame: 6 months
Treatment costs
Treatment costs from admission until hospital discharge
Time frame: 6 months
Plan to share: No
No publications or documents are linked to this record.
Started May 2021 (actual). Primary completion is estimated for Dec 2027, 79 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pancreatitis, Acute Necrotizing →
Orlando Health, Inc.